619
Views & Citations10
Likes & Shares
The demand for biomarkers in Multiple
Sclerosis (MS) is a subject of great interest in neuroimmunology. The use of
biomarkers of therapeutic response is one of the most relevant issues in MS.
The study of microRNAs (miRNAs) as possible biomarkers of MS treatment is
increasing exponentially.
However, the demonstration of dysregulated
miRNAs in B cells in MS still has few scientific articles. Fewer studies have
studied the correlation between dysregulated miRNAs in B cells and natalizumab
(NTZ) therapy. B cells demonstrate impact on the pathogenesis of MS, thus the
study of miRNAs as possible biomarkers in these cells is of important clinical
interest.
Our review provides the feasibility of
miRNAs as possible biomarkers for the evaluation of clinical response during
NTZ treatment, the risk for a CIS to evolve into a RRMS and the risk of PML
during NTZ therapy. All of this is possible by analyzing expression profiles of
miRNAs in MS patients. It may also help to delineate the molecular mechanisms
in MS pathogenesis in future.
We summarized the major changes in the
expression of each miRNA studied during NTZ therapy. We suggest and encourage
further clinical researches to evaluate miRNAs as biomarkers of therapeutic
response in MS during NTZ treatment. Therefore, is it possible microRNAs will
be used in the future as biomarkers of therapeutic response in MS patients?
Keywords: microRNA, Natalizumab, Multiple sclerosis, Therapy, Biomarkers
QUICK LINKS
- SUBMIT MANUSCRIPT
- RECOMMEND THE JOURNAL
-
SUBSCRIBE FOR ALERTS
RELATED JOURNALS
- Journal of Rheumatology Research (ISSN:2641-6999)
- Journal of Psychiatry and Psychology Research (ISSN:2640-6136)
- Chemotherapy Research Journal (ISSN:2642-0236)
- Advance Research on Alzheimers and Parkinsons Disease
- Journal of Blood Transfusions and Diseases (ISSN:2641-4023)
- Journal of Ageing and Restorative Medicine (ISSN:2637-7403)
- Journal of Nursing and Occupational Health (ISSN: 2640-0845)